What is Moderna, Inc. share price today?

Moderna, Inc. (MRNA) share price today is {{live_price}}.

Can Indians buy Moderna, Inc. shares?

Yes, Indians can invest in the Moderna, Inc. (MRNA) from India. With INDmoney, you can buy Moderna, Inc. at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Moderna, Inc. at zero transaction cost.

How can I buy Moderna, Inc. shares from India?

It is very easy to buy Moderna, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Moderna, Inc. be purchased?

Yes, you can buy fractional shares of Moderna, Inc. with INDmoney app.

What are the documents required to start investing in Moderna, Inc. stocks?

To start investing in Moderna, Inc., You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Moderna, Inc.

Today’s highest price of Moderna, Inc. (MRNA) is {{1_rba_end}}. Today’s lowest price of Moderna, Inc. (MRNA) is {{1_rba_st}}.

What is today's market capitalisation of Moderna, Inc.

Today's market capitalisation of Moderna, Inc. MRNA is 41.7B

What is the 52 Week High and Low Range of Moderna, Inc.

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Moderna, Inc. is down from its 52 Week High?

Moderna, Inc. (MRNA) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Moderna, Inc. is up from its 52 Week low?

Moderna, Inc. (MRNA) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Moderna, Inc.?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Moderna, Inc.

Mr. Stephane Bancel is the current Chief Executive Officer (CEO) of Moderna, Inc..

Home>
US Stocks>
Moderna, Inc.

Moderna, Inc. (MRNA)

$107.97

+1.79

(+1.69%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Moderna, Inc.

Increasing Revenue
Revenue is up for the last 3 quarters, 344.0M → 2.81B (in $), with an average increase of 58.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.63B → 217.0M (in $), with an average increase of 1772.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 71.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 279.7%

Performance

$105.41
$108.19
$107.97
2.37%
Downside
Day's Volatility :2.57%
Upside
0.2%
$62.55
$142.79
$107.97
42.07%
Downside
52 Weeks Volatility :56.19%
Upside
24.39%

Returns

Period	Moderna, Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	4.29%	0.5%	1.0%
6 Months	39.75%	11.7%	23.9%
1 Year	-18.77%	6.2%	31.7%
3 Years	-40.22%	13.5%	10.4%

Highlights

Market Capitalization	41.7B
Book Value	$36.27
Earnings Per Share (EPS)	-12.33
PEG Ratio	0.0
Wall Street Target Price	132.36

Profit Margin	-68.84%
Operating Margin TTM	0.21%

Return On Assets TTM	-11.97%
Return On Equity TTM	-28.59%

Revenue TTM	6.8B
Revenue Per Share TTM	17.93
Quarterly Revenue Growth YOY	-44.7%
Gross Profit TTM	10.6B
EBITDA	-3.6B
Diluted Eps TTM	-12.33
Quarterly Earnings Growth YOY	-0.85

EPS Estimate Current Year	-7.22
EPS Estimate Next Year	-5.19
EPS Estimate Current Quarter	-0.9
EPS Estimate Next Quarter	-2.62

Analyst Recommendation

Buy

55%Buy

37%Hold

6%Sell

Based on 29 Wall street analysts offering stock ratings for Moderna, Inc.(by analysts ranked 0 to 5 stars)

Based on 29 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 22.59%

Current $107.97

Target $132.36

Company Financials

	FY18	Y/Y Change
Revenue	122.5M	↓ 30.77%
Net Income	-384.7M	↑ 50.34%
Net Profit Margin	-314.04%	↓ 169.43%

	FY19	Y/Y Change
Revenue	48.0M	↓ 60.79%
Net Income	-514.0M	↑ 33.6%
Net Profit Margin	-1.1K%	↓ 756.03%

	FY20	Y/Y Change
Revenue	274.5M	↑ 471.43%
Net Income	-747.1M	↑ 45.34%
Net Profit Margin	-272.16%	↑ 797.91%

	FY21	Y/Y Change
Revenue	17.7B	↑ 6361.44%
Net Income	12.2B	↓ 1733.33%
Net Profit Margin	68.8%	↑ 340.96%

	FY22	Y/Y Change
Revenue	19.3B	↑ 8.61%
Net Income	8.4B	↓ 31.47%
Net Profit Margin	43.41%	↓ 25.39%

	FY23	Y/Y Change
Revenue	6.8B	↓ 64.94%
Net Income	-4.7B	↓ 156.37%
Net Profit Margin	-69.8%	↓ 113.21%

	Q3 FY22	Q/Q Change
Revenue	3.2B	↓ 29.48%
Net Income	1.0B	↓ 52.53%
Net Profit Margin	32.39%	↓ 15.73%

	Q4 FY22	Q/Q Change
Revenue	5.1B	↑ 57.89%
Net Income	1.5B	↑ 40.46%
Net Profit Margin	28.82%	↓ 3.57%

	Q1 FY23	Q/Q Change
Revenue	1.9B	↓ 63.38%
Net Income	79.0M	↓ 94.61%
Net Profit Margin	4.24%	↓ 24.58%

	Q2 FY23	Q/Q Change
Revenue	344.0M	↓ 81.53%
Net Income	-1.4B	↓ 1846.84%
Net Profit Margin	-401.16%	↓ 405.4%

	Q3 FY23	Q/Q Change
Revenue	1.8B	↑ 432.27%
Net Income	-3.6B	↑ 163.04%
Net Profit Margin	-198.25%	↑ 202.91%

	Q4 FY23	Q/Q Change
Revenue	2.8B	↑ 53.63%
Net Income	217.0M	↓ 105.98%
Net Profit Margin	7.71%	↑ 205.96%

	FY18	Y/Y Change
Total Assets	2.0B	↑ 80.93%
Total Liabilities	431.9M	↓ 5.94%

	FY19	Y/Y Change
Total Assets	1.6B	↓ 19.0%
Total Liabilities	414.6M	↓ 4.0%

	FY20	Y/Y Change
Total Assets	7.3B	↑ 361.6%
Total Liabilities	4.8B	↑ 1051.77%

	FY21	Y/Y Change
Total Assets	24.7B	↑ 236.24%
Total Liabilities	10.5B	↑ 120.38%

	FY22	Y/Y Change
Total Assets	25.9B	↑ 4.82%
Total Liabilities	6.7B	↓ 36.0%

	FY23	Y/Y Change
Total Assets	18.4B	↓ 28.74%
Total Liabilities	4.6B	↓ 32.12%

	Q3 FY22	Q/Q Change
Total Assets	26.1B	↑ 0.05%
Total Liabilities	8.1B	↑ 0.07%

	Q4 FY22	Q/Q Change
Total Assets	25.9B	↓ 0.76%
Total Liabilities	6.7B	↓ 16.48%

	Q1 FY23	Q/Q Change
Total Assets	24.1B	↓ 6.7%
Total Liabilities	5.3B	↓ 21.87%

	Q2 FY23	Q/Q Change
Total Assets	21.9B	↓ 9.29%
Total Liabilities	4.9B	↓ 6.21%

	Q3 FY23	Q/Q Change
Total Assets	19.5B	↓ 11.12%
Total Liabilities	6.0B	↑ 21.48%

	Q4 FY23	Q/Q Change
Total Assets	18.4B	↓ 5.26%
Total Liabilities	4.6B	↓ 23.74%

	FY18	Y/Y Change
Operating Cash Flow	-330.9M	↓ 0.19%
Investing Cash Flow	-372.5M	↓ 189.24%
Financing Cash Flow	1.2B	↑ 730163.1%

	FY19	Y/Y Change
Operating Cash Flow	-459.0M	↑ 38.72%
Investing Cash Flow	-14.9M	↓ 95.99%
Financing Cash Flow	51.1M	↓ 95.83%

	FY20	Y/Y Change
Operating Cash Flow	2.0B	↓ 541.64%
Investing Cash Flow	-1.7B	↑ 11087.21%
Financing Cash Flow	2.0B	↑ 3877.22%

	FY21	Y/Y Change
Operating Cash Flow	13.6B	↑ 571.94%
Investing Cash Flow	-8.5B	↑ 409.77%
Financing Cash Flow	-873.0M	↓ 142.94%

	FY22	Y/Y Change
Operating Cash Flow	5.0B	↓ 63.43%
Investing Cash Flow	-5.2B	↓ 39.27%
Financing Cash Flow	-3.4B	↑ 294.96%

	Q3 FY22	Q/Q Change
Operating Cash Flow	252.0M	↓ 17.11%
Investing Cash Flow	945.0M	↓ 182.03%
Financing Cash Flow	-1.0B	↓ 21.55%

	Q4 FY22	Q/Q Change
Operating Cash Flow	1.7B	↑ 559.52%
Investing Cash Flow	-1.0B	↓ 210.9%
Financing Cash Flow	-438.0M	↓ 57.93%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-1.2B	↓ 173.71%
Investing Cash Flow	2.0B	↓ 291.89%
Financing Cash Flow	-542.0M	↑ 23.74%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-915.0M	↓ 25.31%
Investing Cash Flow	1.9B	↓ 3.33%
Financing Cash Flow	-668.0M	↑ 23.25%

	Q3 FY23	Q/Q Change
Operating Cash Flow	-1.6B	↑ 74.86%
Investing Cash Flow	789.0M	↓ 59.41%
Financing Cash Flow	-58.0M	↓ 91.32%

Technicals Summary

Sell

Neutral

Buy

Moderna, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Moderna, Inc.	-1.15%	39.75%	-18.77%	-40.22%	304.34%
Regeneron Pharmaceuticals, Inc.	-7.56%	12.46%	14.48%	77.72%	159.17%
Novo Nordisk A/s	-2.8%	32.13%	52.48%	239.51%	414.16%
Vertex Pharmaceuticals Incorporated	-4.96%	10.08%	23.01%	83.3%	130.08%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Moderna, Inc.	24.73	NA	0.0	-7.22	-0.29	-0.12	NA	36.27
Regeneron Pharmaceuticals, Inc.	26.04	26.04	1.46	45.0	0.16	0.08	NA	242.47
Novo Nordisk A/s	47.43	47.43	2.4	3.35	0.88	0.23	0.01	23.9
Vertex Pharmaceuticals Incorporated	28.81	28.81	0.53	16.75	0.23	0.13	NA	68.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Moderna, Inc.	Buy	$41.7B	304.34%	24.73	-68.84%
Regeneron Pharmaceuticals, Inc.	Buy	$99.5B	159.17%	26.04	30.14%
Novo Nordisk A/s	Buy	$562.8B	414.16%	47.43	36.03%
Vertex Pharmaceuticals Incorporated	Buy	$103.6B	130.08%	28.81	36.68%

Institutional Holdings

Baillie Gifford & Co Limited.
11.92%
Vanguard Group Inc
8.86%
BlackRock Inc
6.61%
State Street Corporation
3.82%
Flagship Ventures Management, Inc.
2.52%
Goldman Sachs Group Inc
2.38%

Company Information

Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the Moderna COVID-19 vaccine. The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna, Inc. has a market cap of $41.68 Billion. It has a P.E ratio of -8.84. The shares of Moderna, Inc. are trading at $106.18. .

Organization	Moderna, Inc.
Employees	5600
CEO	Mr. Stephane Bancel
Industry	Health Technology